Treatment of pediatric Hodgkin disease avoiding radiotherapy: Excellent outcome with the Rotterdam-HD-84-Protocol

Pediatric Blood and Cancer

Volumn 43, Issue 1, 2004, Pages 8-16

  Hakvoort Cammel, Friederike G A J ^a,b   Buitendijk, Saskia ^a   Van Den Heuvel Eibrink, Marry ^a   Hählen, Karel ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Chemotherapy; Children; Hodgkin disease; Outcome; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEART DISEASE; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; LUNG DISEASE; MALE; MEDIASTINUM MASS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; NETHERLANDS; PREDNISONE; PROCARBAZINE; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; VINBLASTINE; VINCRISTINE;

EID: 2942626150     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20031     Document Type: Article

References (42)

1. Hudson MM, Donaldson SS. Treatment of pediatric Hodgkin lymphoma. Semin Hematol 1999;36:313-323.
2. Donaldson SS, Link MP. Combined modality trials with low-dose radiation therapy and MOPP chemotherapy for children with Hodgkin disease. J Clin Oncol 1987;5:742-749.
3. Jenkin D, Doyle J, Berry M, et al. Hodgkin disease in children: Treatment results with MOPP and low-dose, extended-field irradiation without laparotomy: Late results and toxicity. Med Pediatr Oncol 1990;18:265-272.
4. Santoro A, Bonfante V, Bonadonna G, et al. Alternating drug combinations in the treatment of advanced Hodgkin disease. N Engl J Med 1982;306:770-775.
5. Young CW. Epirubicin: A therapeutically active doxorubicin analogue with reduced cardiotoxicity. In: Bonodonna G, editor. International symposium on advances in anthracycline chemotherapy. Italy: Milan; 1984. pp 183-188.
6. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin disease Staging Classification. Cancer Res 1971;31:1860-1861.
7. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin disease. Cancer Res 1966;26:1063-1081.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statistical Assoc 1958;53:457-481.
9. Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on lung volume measurements. Official statement of the European Respiratory Society. Eur Resp J 1995;8:492-506.
10. Quanjer PhH, Borsboom GJJM, Brunekreef B, et al. Spirometric reference values for white European children and adolescents: Polgar revisited. Pediatr Pulmonol 1995;19:135-142.
11. Stam H, Beek van der A, Grunberg K, et al. Pulmonary diffusing capacity at reduced alveolar volumes in children. Pedriatr Pulmonol 1996;21:84-89.
12. Behrendt H, Bunningen van BNFM, Leeuwen van EF. Treatment of Hodgkin disease in children with or without radiotherapy. Cancer 1987;59:1870-1873.
13. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 1997;15:2769-2779.
14. Hutchinson RJ, Fryer CJ, Davis PC, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin disease in children: Results of the Children's Cancer Group Phase III Trial. J Clin Oncol 1998;16:897-906.
15. Berg van den H, Stuve W, Behrendt H. Treatment of Hodgkin disease in children with alternating Mechlorethamine, Vincristine, Procarbazine, and Prednisone (MOPP) and Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) courses without radiotherapy. Med Pediatr Oncol 1997;29:23-27.
16. Ekert H, Waters KD. Results of treatment of 18 children with Hodgkin disease with MOPP chemotherapy as only treatment modality. Med Pediatr Oncol 1983;11:322-326.
17. Oberlin O, Leverger G, Pacquement H, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:1602-1608.
18. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin disease: Response-adapted chemotherapy with Etoposide, Bleomycin, Vinblastine, and Prednisone before low-dose radiation therapy-Results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000;18:1500-1507.
19. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin disease. J Clin Oncol 1998;16:818-829.
20. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin disease who achieve a complete response on chemotherapy. J Clin Oncol 2002;18:3765-3771.
21. Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low-dose involved field radiotherapy in pediatric Hodgkin disease: The Stanford experience. J Clin Oncol 1994;12:2160-2166.
22. Zijlstra JM, Dressel AJN, Mens JW, et al. Radiation therapy in early stage Hodgkin disease: Long term results and adverse effects. The Hematology J 2002;3:178-184.
23. Shankar AG, Ashley S, Radford M, et al, Does histology influence outcome in childhood Hodgkin disease? Results from the United Kingdom Children's Cancer Study Group. J Clin Oncol 1997;15:2622-2630.
24. Cersosimo RJ, Hong WK. Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 1986;4:425-439.
25. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin disease in children and adolescents. J Clin Oncol 1993;7:1208-1215.
26. Comis RL. Bleomycin pulmonary toxicity: Current status and future directions. Sem Oncol 1992;19(Suppl 5):64-70.
27. Goldiner PL, Schweizer O. The hazards of anesthesia and surgery in bleomycin-treated patients. Semin Oncol 1979;6:121-124.
28. Mefferd JM, Donaldson SS, Link MP. Pediatric Hodgkin disease: Pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys 1989;16:679-685.
29. Constine LS, Donaldson SS, McDougall IR, et al. Thyroid dysfunction after radiotherapy in children with Hodgkin disease. Cancer 1984;53:878-883.
30. Little J. Epidemiology of childhood cancer. Vol. 149. Lyon; IARC Scientific Publications; 1999, pp 38-40.
31. Stiller CA. What causes Hodgkin disease in children? Eur J Cancer 1998;34:523-528.
32. Buyukpamukcu M, Atahan L, Caglar M, et al. Hodgkin disease in Turkish children: Clinical characteristics and treatment results of 210 patients. Pediatr Hematol Oncol 1999;16:119-129.
33. Shugart YY, Hemminki K, Vaittinen P, et al. A genetic study of Hodgkin lymphoma: An estimate of heritability and anticipation based on the familial cancer database in Sweden. Hum Genet 2000;106:553-556.
34. Green DM. Longterm complications of therapy for cancer in childhood and adolescence. Baltimore, Maryland: The Johns Hopkins university Press; 1989, pp 60-61.
35. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin disease. N Engl J Med 1996;334:745-751.
36. Meadows AT, Obringer AC, Marrero O, et al. Second malignant neoplasms following childhood Hodgkin disease: Treatment and splenectomy as risk factors. Med Pediatr Oncol 1989;17:477-484.
37. Leeuwen van EF, Klokman WJ, Veer van't MB, et al. Long-term risk of second malignancy in survivors of Hodgkin disease treated during adolescence or young adulthood. J Clin Oncol 2000;18:487-497.
38. Donaldson SS. Pediatric Hodgkin disease - Up, up and beyond. Int J Radiat Oncol Biol Phys 2002;54:1-8.
39. Donaldson SS. A Discourse: The 2002 Wataru W. Sutow Lecture: Hodgkin Disease in children-Perspectives and progress. Med Pediatr Oncol 2003;40:73-81.
40. Donaldson SS, Hudson MM, Lamborn KR, et al. The VAMP and low-dose, involved-field radiotherapy for children and adolescents with favourable, early-stage Hodgkin disease: Results of a prospective clinical trial. J Clin Oncol 2002;20:3081-3087.
41. Schellong G, Pötter R, Brämswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin disease: The German-Austrian multicenter trial DAL-HD-90. J Clin Oncol 1999;17:3736-3744.
42. Berg van den H, Verhulst L, Behrendt H. Persistent mediastinal mass is not indicative of recurrence after chemotherapy only in paediatric Hodgkin disease. British J Haem 2000;109(1):104-108.